Miranova (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Miranova, are a combined oral contraceptive presented as an oral tablet for oral use. They are prescribed to prevent pregnancy in women of reproductive age by inhibiting ovulation and creating conditions unfavorable for fertilization and implantation and maintaining menstrual regularity.

GNH USA supplies Miranova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miranova, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

Contraception: prevents pregnancy by suppressing ovulation and altering cervical mucus. Menstrual cycle regulation: helps establish regular menstrual bleeding patterns. Dysmenorrhea management: reduces menstrual pain associated with ovulatory cycles.

Miranova may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Stroke - Myocardial infarction - Hepatic adenoma - Severe hypertension - Anaphylactic reaction

Before prescribing Miranova, clinicians should consider several safety measures. - Assess thrombotic risk: evaluate patient history of clotting disorders before prescribing. - Avoid smoking: especially in women over 35 years of age. - Monitor blood pressure: check regularly during therapy. - Consider liver function: contraindicated in active hepatic disease. - Contraindicated in pregnancy: product is classified as pregnancy category X. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Miranova can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive efficacy. - Rifampin and other rifamycins: lower plasma hormone levels, risking breakthrough bleeding. - St. John’s wort: herbal inducer that may compromise contraceptive effect.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: may slightly decrease hormone concentrations. - Antifungal agents (e.g., fluconazole): can increase estrogen exposure, heightening side‑effect risk. - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate mood‑related side effects.